Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients.
about
Serum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 DiabetesRecurrence of autoimmunity following pancreas transplantation.A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice.Clinical islet xenotransplantation: how close are we?Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remainAlloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes.Immune antibody monitoring predicts outcome in islet transplantation.Genetically engineered human islets protected from CD8-mediated autoimmune destruction in vivo.Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcomeOutcomes of Pancreatic Islet Allotransplantation Using the Edmonton Protocol at the University of Chicago.Current advances and travails in islet transplantation.Autologous and Allogenous Antibodies in Lung and Islet Cell Transplantation.Immune monitoring of pancreatic islet graft: towards a better understanding, detection and treatment of harmful events.Type 1 diabetes: etiology, immunology, and therapeutic strategies.The potential of multimer technologies in type 1 diabetes prediction strategies.Immune and cell therapy in type 1 diabetes: too little too late?T cell autoreactivity in the transplant milieu.The multiple origins of Type 1 diabetes.Progress in immune-based therapies for type 1 diabetes.Toward engineering a novel transplantation site for human pancreatic islets.Immune monitoring of islet and pancreas transplant recipients.Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase.Immune modulation in humans: implications for type 1 diabetes mellitus.Interleukin-7 and type 1 diabetes.Monitoring Inflammation, Humoral and Cell-mediated Immunity in Pancreas and Islet Transplants.Recurrence of autoimmunity in pancreas transplant patients: research update.Transplantable bioartificial pancreas devices: current status and future prospects.Transplantation of Encapsulated Pancreatic Islets as a Treatment for Patients with Type 1 Diabetes Mellitus.Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2.Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model.Plasma GAD65, a Marker for Early β-Cell Loss After Intraportal Islet Cell Transplantation in Diabetic Patients.Local autoantigen expression as essential gatekeeper of memory T-cell recruitment to islet grafts in diabetic hosts.Stem cells as a tool to improve outcomes of islet transplantation.Pretransplant immune parameters associate with islet allograft outcome: implications for transplant strategy?Multicenter Australian trial of islet transplantation: improving accessibility and outcomes.Identification of Donor Origin and Condition of Transplanted Islets In Situ in the Liver of a Type 1 Diabetic Recipient.Optimizing Multiplexed Detections of Diabetes Antibodies via Quantitative Microfluidic Droplet Array.Autoreactive T cells in type 1 diabetes.
P2860
Q28552483-D48F24E2-7BB9-4DD0-8461-2C170B7DFAA0Q33599426-60A95A61-8372-46EE-B896-0E64326BE76FQ34082857-442A4F59-CF91-4C2E-A4C3-606FA5755678Q34313171-473175AE-1A3F-4019-9038-4FF765FD6AE2Q35976614-E332E75F-BADA-47AB-AC32-985225734507Q36290283-A539FA77-2A98-457A-A1A1-0A143EFE13D6Q36666407-FFD8E065-395B-4758-947D-28D6624421BEQ36796037-6B4BAD3B-C5AA-4656-BC2A-E35C85DAC982Q36796105-990F3A9A-4141-4257-9D25-6B8E87AC827AQ37073103-D5EA3180-7F2F-4ACC-9AF7-B1E25C43F88FQ37088225-4F80436F-5AE5-4B76-8143-B008EA4E577BQ37346582-C503D00A-C5F2-40CD-B384-AA2910B48FE3Q37360411-242DBDA3-C01D-437B-B266-DA752B1E615AQ37528715-34353361-1D66-4CA6-BC57-128307C899DEQ37809052-495BA4BF-AF71-455B-8A15-AF7A8FD27F18Q37830198-754348F9-11C7-4970-9722-9C99C7EF69EDQ37838895-D91BA2FE-801E-4616-9E65-EA5EB2CCD7D6Q37853194-5CC19C35-7406-49BC-9859-5F7363C71FE1Q38014104-98B21962-07D1-47DE-9E78-8179DF10E08BQ38062580-30B52016-A447-467F-96CA-C95644BD78A2Q38097920-53B30AA9-4BD6-4E68-941F-6A3885E53928Q38101322-C5C9C3DF-C648-4D1B-A1B6-1D8D25A3023FQ38128768-C55C9D4D-DD51-4DEC-B1F4-2B39BB35BBF3Q38161556-91361CB0-F801-40E8-9EE8-B5552CEC8ADFQ38182297-B909C3A2-655F-4134-9D3F-6E92F1E986FEQ38226437-DC69281B-25ED-4641-9830-40BBDDD2A75CQ38380235-2A0857F5-BBB1-4E3D-8B73-2507533CD773Q38386317-45467ED6-42A4-4420-9A48-E653F03EA50AQ38528327-E81F96D4-A46A-43C1-A40F-02C8FDC9290BQ38630043-111BB28F-9877-4C81-87FC-6A6834F66B14Q38807853-80E67EF7-9FE5-4470-936D-963DC86358E3Q39793666-9990899A-C2A8-4242-9B9E-A6443799754AQ41767345-6CF4003E-C308-4F4C-9EB4-BE4F4AC694BCQ41812609-58A165A4-CF3A-4CA7-BCB4-DD5554DBDDA1Q42324113-CE6BE9AA-5AC9-4D30-80F8-45E84777D253Q42563613-7F1164FA-B0B6-4D5E-9BC9-F31F107F5B10Q44842989-BAF1E50F-318C-4D02-AABC-ECFB4A7DF1B3Q45913920-361B0026-52EC-4D37-B5B3-12E5D111624DQ47153962-6E74329E-D317-458A-82C3-F02342EC322FQ48004838-EC7C74D7-AAA4-4302-B7BC-E058942BC689
P2860
Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Differences in baseline lympho ...... n in type 1 diabetic patients.
@en
Differences in baseline lympho ...... n in type 1 diabetic patients.
@nl
type
label
Differences in baseline lympho ...... n in type 1 diabetic patients.
@en
Differences in baseline lympho ...... n in type 1 diabetic patients.
@nl
prefLabel
Differences in baseline lympho ...... n in type 1 diabetic patients.
@en
Differences in baseline lympho ...... n in type 1 diabetic patients.
@nl
P2093
P2860
P50
P356
P1433
P1476
Differences in baseline lympho ...... n in type 1 diabetic patients.
@en
P2093
Babak Movahedi
Bart Keymeulen
Bart O Roep
Daniel G Pipeleers
Daniel Jacobs-Tulleneers-Thevissen
Dirk Ysebaert
Frans K Gorus
Jurjen H L Velthuis
Leonard Kaufman
Marc De Waele
P2860
P304
P356
10.2337/DB09-0160
P407
P577
2009-07-14T00:00:00Z